These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 10854138)
1. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma. Fumagalli L; Zucchetti M; Parisi I; Viganò MG; Zecca B; Careddu A; D'Incalci M; Lazzarin A Cancer Chemother Pharmacol; 2000; 45(6):495-501. PubMed ID: 10854138 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia. Bellott R; Auvrignon A; Leblanc T; Pérel Y; Gandemer V; Bertrand Y; Méchinaud F; Bellenger P; Vernois J; Leverger G; Baruchel A; Robert J Cancer Chemother Pharmacol; 2001; 47(1):15-21. PubMed ID: 11221955 [TBL] [Abstract][Full Text] [Related]
3. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. Zucchetti M; Boiardi A; Silvani A; Parisi I; Piccolrovazzi S; D'Incalci M Cancer Chemother Pharmacol; 1999; 44(2):173-6. PubMed ID: 10412954 [TBL] [Abstract][Full Text] [Related]
4. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. Lebbé C; Blum L; Pellet C; Blanchard G; Vérola O; Morel P; Danne O; Calvo F AIDS; 1998 May; 12(7):F45-9. PubMed ID: 9619797 [TBL] [Abstract][Full Text] [Related]
5. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia. Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654 [TBL] [Abstract][Full Text] [Related]
6. Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia. Pea F; Russo D; Michieli M; Baraldo M; Ermacora A; Damiani D; Baccarani M; Furlanut M Cancer Chemother Pharmacol; 2000; 46(4):279-86. PubMed ID: 11052625 [TBL] [Abstract][Full Text] [Related]
7. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. Gill PS; Wernz J; Scadden DT; Cohen P; Mukwaya GM; von Roenn JH; Jacobs M; Kempin S; Silverberg I; Gonzales G; Rarick MU; Myers AM; Shepherd F; Sawka C; Pike MC; Ross ME J Clin Oncol; 1996 Aug; 14(8):2353-64. PubMed ID: 8708728 [TBL] [Abstract][Full Text] [Related]
8. Resolution of severe Kaposi's sarcoma after initiation of antiretroviral triple therapy. Jung C; Bogner JR; Goebel F Eur J Med Res; 1998 Sep; 3(9):439-42. PubMed ID: 9737891 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma. Girard PM; Bouchaud O; Goetschel A; Mukwaya G; Eestermans G; Ross M; Rozenbaum W; Saimot AG AIDS; 1996 Jun; 10(7):753-7. PubMed ID: 8805866 [TBL] [Abstract][Full Text] [Related]
11. Kaposi's sarcoma: DaunoXome approved. AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485 [TBL] [Abstract][Full Text] [Related]
12. Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma--drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study. Nannan Panday VR; Hoetelmans RM; van Heeswijk RP; Meenhorst PL; Inghels M; Mulder JW; Beijnen JH Cancer Chemother Pharmacol; 1999; 43(6):516-9. PubMed ID: 10321513 [TBL] [Abstract][Full Text] [Related]
13. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study). Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393 [TBL] [Abstract][Full Text] [Related]
14. Paclitaxel for treating KS. Proj Inf Perspect; 1997 Nov; (23):15. PubMed ID: 11365372 [TBL] [Abstract][Full Text] [Related]
15. Liposomal anthracycline chemotherapy and the risk of second malignancies in patients with Kaposi's sarcoma (KS). Bendle M; Pealing J; Papanastasopoulos P; Bower M Cancer Chemother Pharmacol; 2014 Sep; 74(3):611-5. PubMed ID: 25055936 [TBL] [Abstract][Full Text] [Related]
16. Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. Rosenthal E; Poizot-Martin I; Saint-Marc T; Spano JP; Cacoub P; Am J Clin Oncol; 2002 Feb; 25(1):57-9. PubMed ID: 11823698 [TBL] [Abstract][Full Text] [Related]
17. Complete regression of AIDS-related Kaposi's sarcoma-associated human herpesvirus-8 during therapy with indinavir. Martinelli C; Zazzi M; Ambu S; Bartolozzi D; Corsi P; Leoncini F AIDS; 1998 Sep; 12(13):1717-9. PubMed ID: 9764794 [No Abstract] [Full Text] [Related]
18. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients. Kappelhoff BS; Huitema AD; Sankatsing SU; Meenhorst PL; Van Gorp EC; Mulder JW; Prins JM; Beijnen JH Br J Clin Pharmacol; 2005 Sep; 60(3):276-86. PubMed ID: 16120066 [TBL] [Abstract][Full Text] [Related]
19. Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study). Florence E; Dreezen C; Desmet P; Smets E; Fransen K; Vandercam B; Pelgrom J; Clumeck N; Colebunder R Antivir Ther; 2001 Dec; 6(4):255-62. PubMed ID: 11878407 [TBL] [Abstract][Full Text] [Related]